Dr. Michael Castagna Interview with Pharmacy Edge Magazine

Dr. Michael Castagna Interview with Pharmacy Edge Magazine

"We had the pleasure of interviewing Dr. Michael Castagna, CEO of Mannkind Corporation for July's issue of Pharmacy Edge Magazine, which is our monthly publication for Independent Pharmacies, Pharmacists and Pharmacy Buyers."

Watch Dr. Michael Castagna's Interview Below

Michael Castagna

Dr. Michael Castagna is the Chief Executive Officer for Mannkind Corp. Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs, and Vice President, Global Lifecycle Management.

Prior to Amgen, Dr. Castagna, was Executive Director of Bristol-Myers Squibb’s Immunology franchise, where he served as co-lead to relaunch Orencia IV and launch Orencia SC, both rheumatoid arthritis drugs. Before BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and Division Head for Biopharmaceuticals, North America, where he established the US Biologics Business Unit and relaunched its lead product, Omnitrope, a human growth hormone.

Prior to Sandoz, Dr. Castagna held a variety of positions with EMD (Merck), Serono, Pharmasset and DuPont Pharmaceuticals. Dr. Castagna serves on the board of directors of Pet Partners headquartered in Bellevue, Washington.

Dr. Castagna received his Bachelors of Science – Pharmacy degree from Philadelphia College of Pharmacy, his Doctor of Pharmacy from Massachusetts College of Pharmacy, and his MBA from the Wharton School of Business at the University of Pennsylvania.

"MannKind Corporation is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes."

FDA-approved AFREZZA is the only inhaled insulin working to help control adult diabetics’ blood sugar during mealtime. AFREZZA is fast-acting insulin that helps you reach and maintain your A1C goal. The rapid-acting insulin reaches maximum (peak) level in 12 to 15 minutes and can stay active for up to 3 hours.

 

7 347